UroGen Pharma Ltd (URGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.28B
Last updated: Nov 17, 2026 at 11:05 AM ET
UroGen Pharma Ltd (URGN) Financials: Revenue, Profit and Cash Flow
UroGen Pharma reported revenue of $109.79M for the fiscal year ended Dec 31, 2025, up 21.4% from the year before. That year, net income was -$153.49M with a net margin of -139.8%, operating cash flow was -$162.44M and free cash flow was -$162.73M. The quarter ended Sep 30, 2026 had revenue of $89.00M and net income of -$1.46M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue grew from $17.53M, a compound annual rate of 22.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $109.79M | +21.4% | 88.7% | -113.7% | -139.8% |
| Dec 2024 | $90.40M | +9.3% | 90.2% | -107.1% | -140.4% |
| Dec 2023 | $82.71M | +28.5% | 88.7% | -79.2% | -123.6% |
| Dec 2022 | $64.36M | +34.0% | 88.1% | -122.8% | -170.6% |
| Dec 2021 | $48.04M | +307.2% | 89.3% | -192.1% | -230.7% |
| Dec 2020 | $11.80M | +65450.0% | 91.4% | -1074.2% | -1088.9% |
| Dec 2019 | $18.00K | -98.4% | 100.0% | -608211.1% | -584144.4% |
| Dec 2018 | $1.13M | -86.2% | -59.8% | -6842.2% | -6707.2% |
| Dec 2017 | $8.16M | -53.5% | 92.6% | -244.5% | -245.2% |
| Dec 2016 | $17.53M | N/A | 99.8% | 4.6% | -11.1% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109.79M | $90.40M | $82.71M | $64.36M | $48.04M | $11.80M | $18.00K | $1.13M | $8.16M | $17.53M |
| Cost of revenue | $12.45M | $8.88M | $9.36M | $7.65M | $5.16M | $1.01M | $0 | $1.80M | $600.00K | $28.00K |
| Gross profit | $97.34M | $81.52M | $73.35M | $56.70M | $42.88M | $10.79M | $18.00K | -$675.00K | $7.56M | $17.50M |
| Research and development | $67.11M | $57.15M | $45.61M | $52.91M | $47.64M | $47.31M | $49.30M | $36.93M | $18.70M | $10.29M |
| Operating income | -$124.86M | -$96.78M | -$65.54M | -$79.04M | -$92.29M | -$126.74M | -$109.48M | -$77.18M | -$19.95M | $798.00K |
| Net income | -$153.49M | -$126.87M | -$102.24M | -$109.78M | -$110.82M | -$128.48M | -$105.15M | -$75.66M | -$20.00M | -$1.94M |
| EBITDA | N/A | N/A | N/A | N/A | N/A | -$125.88M | -$108.73M | -$76.76M | -$19.74M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $89.00M | $72.46M | $50.96M | $37.84M | $27.48M | $24.21M | $20.25M | $24.57M | $25.20M | $21.85M | $18.78M | $23.53M |
| Gross profit | $81.50M | $65.88M | $46.82M | $34.55M | $24.20M | $20.66M | $17.92M | $22.09M | $22.75M | $19.62M | $17.05M | $21.24M |
| Operating income | $8.33M | $111.00K | -$20.26M | -$19.11M | -$27.39M | -$41.45M | -$36.91M | -$27.66M | -$17.55M | -$25.84M | -$25.74M | -$14.61M |
| Net income | -$1.46M | -$14.35M | -$23.57M | -$26.36M | -$33.35M | -$49.94M | -$43.84M | -$37.51M | -$23.67M | -$33.40M | -$32.29M | -$26.02M |
Balance Sheet
As of Dec 2025, long-term debt of $122.21M exceeded cash and equivalents by $11.46M. Shareholder equity was negative, at -$105.47M, as total liabilities of $305.93M exceeded total assets of $200.46M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $200.46M | $285.71M | $178.31M | $135.62M | $119.75M | $122.00M | $202.39M | $103.56M | $75.55M | $23.06M |
| Current assets | $186.02M | $276.13M | $169.19M | $128.91M | $114.39M | $115.62M | $148.63M | $102.24M | $74.47M | $22.04M |
| Cash and equivalents | $110.75M | $171.99M | $95.00M | $55.41M | $44.36M | $52.86M | $49.69M | $101.32M | $37.00M | $21.36M |
| Total liabilities | $305.93M | $294.51M | $243.52M | $224.98M | $111.33M | $25.65M | $22.09M | $13.46M | $7.04M | $6.75M |
| Short-term debt | N/A | $1.53M | $819.00K | $941.00K | $3.33M | $1.86M | N/A | N/A | N/A | N/A |
| Long-term debt | $122.21M | $121.73M | $98.55M | $97.54M | $0 | N/A | N/A | N/A | N/A | $3.61M |
| Shareholder equity | -$105.47M | -$8.80M | -$65.21M | -$89.36M | $8.41M | $96.36M | $180.30M | $90.09M | $68.52M | $16.31M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $271.87M | $252.59M | $253.69M | $200.46M | $185.05M | $208.72M | $247.62M | $285.71M | $301.94M | $281.85M | $200.57M | $178.31M |
| Total liabilities | $397.09M | $384.99M | $377.94M | $305.93M | $300.45M | $302.09M | $294.08M | $294.51M | $276.43M | $251.53M | $240.71M | $243.52M |
| Cash and equivalents | $85.56M | $79.13M | $109.97M | $110.75M | $90.04M | $92.90M | $104.03M | $171.99M | $124.92M | $219.97M | $131.44M | $95.82M |
| Shareholder equity | -$125.22M | -$132.40M | -$124.25M | -$105.47M | -$115.41M | -$93.38M | -$46.46M | -$8.80M | $25.52M | $30.31M | -$40.13M | -$65.21M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$162.44M | -$96.77M | -$76.38M | -$87.56M | -$84.89M | -$105.89M | -$71.02M | -$37.33M | -$9.57M | $4.19M |
| Capital expenditures | $289.00K | $295.00K | $194.00K | $254.00K | $752.00K | $1.22M | $325.00K | $560.00K | $271.00K | $695.00K |
| Free cash flow | -$162.73M | -$97.06M | -$76.57M | -$87.81M | -$85.64M | -$107.10M | -$71.34M | -$37.89M | -$9.84M | $3.49M |
| Share repurchases | N/A | N/A | N/A | $160.00K | $144.00K | $66.00K | N/A | $0 | $0 | $579.00K |
| Investing cash flow | $61.56M | -$20.61M | -$953.00K | $1.06M | $4.07M | $93.24M | -$145.59M | $35.29M | -$36.28M | -$719.00K |
| Financing cash flow | $39.92M | $194.62M | $116.93M | $97.13M | $72.32M | $16.53M | $165.25M | $66.42M | $61.59M | -$9.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.20M | -$33.01M | -$45.32M | -$38.33M | -$42.27M | -$39.83M | -$42.02M | -$13.62M | -$27.66M | -$23.75M | -$31.73M | -$13.00M |
| Capital expenditures | $72.00K | $60.00K | $54.00K | $17.00K | $87.00K | $141.00K | $44.00K | $115.00K | $96.00K | $84.00K | $0 | $56.00K |
| Free cash flow | -$15.27M | -$33.07M | -$45.37M | -$38.34M | -$42.36M | -$39.97M | -$42.07M | -$13.73M | -$27.76M | -$23.83M | -$31.73M | -$13.05M |
Frequently Asked Questions About URGN
What is UroGen Pharma's annual revenue?
UroGen Pharma reported revenue of $109.79M for the fiscal year ended Dec 31, 2025.
How fast is UroGen Pharma's revenue growing?
Revenue was up 21.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 19.5%.
Is UroGen Pharma profitable?
No. UroGen Pharma reported net income of -$153.49M for the fiscal year ended Dec 31, 2025, with a net margin of -139.8%.
How much free cash flow does URGN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$162.44M minus capital expenditures of $289.00K produced free cash flow of -$162.73M.
How much debt does UroGen Pharma have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $122.21M and cash and equivalents of $110.75M.
URGN pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts